Wir haben ausgewählte Abstracts von unseren Partnern für Sie zusammengestellt.
AbbVie AG
- POS0847 | Upadacitinib as Monotherapy in Patients With Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 260 Weeks From the SELECT-MONOTHERAPY Study
- POS1524 | Durable clinically-meaningful improvements in health-related quality of life, fatigue, pain, and work productivity among patients with active psoriatic arthritis treated with risankizumab at Week 100
- POS1122 | Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis and an Inadequate Response to Biologic DMARD Therapy: One-Year Results from a Phase 3 Study
Amgen Switzerland AG
- POS0226 | Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
- AB1535 | Efficacy of Apremilast on Whole-Body Inflammation Indices in Patients With Psoriatic Arthritis: Assessments by Whole-Body Magnetic Resonance Imaging in the Phase 4 MOSAIC Study
- POS1527 | Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis
Biogen Switzerland AG
- POS0376 | DOES A MANDATORY SWITCH FROM ORIGINATOR ADALIMUMAB TO BIOSIMILAR GP2017 OR SB5 LEAD TO INCREASED HOSPITAL COSTS? A DANBIO STUDY OF >1,300 PATIENTS WITH INFLAMMATORY ARTHRITIS
- AB1423 | USE OF BIOSIMILAR THERAPIES IN ADULT PATIENTS DIAGNOSED WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE SPANISH REGISTRY OF ADVERSE EVENTS WITH BIOLOGIC THERAPIES (BIOBADASER)
CSL Vifor
- POS0222 | Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in the ADVOCATE Trial
- POS1173 | Long-Term Analysis of Relapse Rates in a European ANCA-Associated Vasculitis (AAV) Cohort for GPA and MPA
- POS1179 | Using Artificial Intelligence to Identify Anti-Neutrophil Cytoplasmatic Antibody (ANCA)-Associated Vasculitis Patients in Electronic Health Record
GlaxoSmithKline AG
- AB0519 | Long-term safety of belimumab among adult patients with sle: pooled data from three open-label extension studies over 11+ years
- AB0904 | Belimumab for the treatment of interstitial lung disease associated with systemic sclerosis: a phase 2/3, randomised, double-blind, placebo-controlled trial
- POS1153 | Applying the working definition of the disease modification criteria to systemic lupus erythematosus treatments from the published literature
Otsuka Pharmaceutical (Switzerland) GmbH
Novartis Pharma Schweiz AG
- POS0278 | Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results From the Extension of the JUNIPERA
- POS1115 | Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status
- OP0058 | Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from the German AQUILA Study
Pfizer AG
- POS0827 | Clinical outcomes of patients with rheumatoid arthritis who discontinued tofacitinib or tumour necrosis factor inhibitors: results from ORAL Surveillance
- POS0232 | Post-marketing safety surveillance of tofacitinib over 9 years in patients with rheumatoid arthritis and psoriatic arthritis
- AB0937 | Tofacitinib efficacy and safety in patients with ankylosing spondylitis by baseline C-reactive protein levels: a post hoc analysis
sanofi-aventis (schweiz) ag
UCB Pharma AG
- POS0683 | An exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis
- POS0679 | Comparison of established and new, preliminary proposed ASAS cut-offs for inflammatory MRI lesions in the sacroiliac joints of axial spondyloarthritis patients and implications for recruitment in clinical studies
- POS0341 | Performance analysis of a deep learning algorithm to detect positive SIJ MRI according to the ASAS definition in axSpA patients